Comment on Rosenstock and Ferrannini. Euglycemic diabetic ketoacidosis: A predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes care 2015; 38:1638-1642

Diabetes Care

Volumn 39, Issue 8, 2016, Pages e138-

  Cushard, William G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; AMINOTRANSFERASE; C PEPTIDE; CHORIONIC GONADOTROPIN; CREATININE; DAPAGLIFLOZIN; ETHYLENE GLYCOL; GLIPIZIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; INSULIN GLARGINE; LACTIC ACID; METFORMIN; PARACETAMOL; SALICYLIC ACID DERIVATIVE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TRIACYLGLYCEROL LIPASE;

ARTERIAL PH; BLOOD CULTURE; CARBOHYDRATE DIET; CASE REPORT; CREATININE BLOOD LEVEL; DIABETIC KETOACIDOSIS; DIET RESTRICTION; DRUG SAFETY; EUGLYCEMIC DIABETIC KETOACIDOSIS; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; KETONURIA; LACTATE BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PRESCRIPTION; PROTEIN BLOOD LEVEL; TOXICOLOGY;

EID: 84980416346     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1948     Document Type: Note

References (3)

1. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015; 38:1638-1642
2. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care 2015; 38:1680-1686
3. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015; 38:1687-1693